Minimum clinical important difference for resilience scale specific to cancer: a prospective analysis

Table 5 Anchor-based MCID and ROC estimates for RS-SC at 3-month (T₁, N = 643)

Indicators	Scale	Anchors	Mean change (95%CI)	Effect Size	Cut-off	Sen	Spe	YI	AUC	P
^aImprovement	RS-SC-10	QoL GHS	3.62 (3.34 to 3.91)	0.48	2.00	0.62	0.69	0.31	0.68	< 0.001
		CD-RISC-10	3.29 (3.10 to 3.48)	0.41	2.00	0.71	0.69	0.40	0.73	< 0.001
		HADS-A	3.05 (2.79 to 3.20)	0.40	2.00	0.61	0.66	0.27	0.67	< 0.001
		HADS-D	3.42 (3.18 to 3.66)	0.44	2.00	0.69	0.64	0.33	0.69	< 0.001
	RS-SC-25	QoL GHS	9.31 (8.83 to 9.81)	0.51	5.50	0.58	0.67	0.25	0.65	< 0.001
		CD-RISC-10	8.56 (8.23 to 8.91)	0.41	5.50	0.72	0.65	0.37	0.70	< 0.001
		HADS-A	8.78 (8.29 to 9.29)	0.44	5.50	0.59	0.67	0.26	0.66	< 0.001
		HADS-D	8.97 (8.50 to 9.44)	0.48	5.50	0.70	0.61	0.31	0.68	< 0.001
^bDeterioration	RS-SC-10	QoL GHS	− 2.59 (− 2.79 to − 2.39)	− 0.35	− 1.50	0.64	0.68	0.32	0.69	< 0.001
		CD-RISC-10	− 2.26 (− 2.39 to − 2.14)	− 0.28	− 1.50	0.71	0.71	0.42	0.74	< 0.001
		HADS-A	− 2.61 (− 2.77 to − 2.43)	− 0.34	− 1.50	0.60	0.66	0.26	0.66	< 0.001
		HADS-D	− 2.48 (− 2.65 to − 2.32)	− 0.32	− 1.50	0.74	0.67	0.41	0.72	< 0.001
	RS-SC-25	QoL GHS	− 6.81 (− 7.18 to − 6.42)	− 0.37	− 4.50	0.61	0.68	0.29	0.68	< 0.001
		CD-RISC-10	− 6.19 (− 6.64 to − 5.93)	− 0.29	− 4.50	0.72	0.69	0.41	0.73	< 0.001
		HADS-A	− 7.05 (− 7.39 to − 6.70)	− 0.36	− 4.50	0.59	0.68	0.27	0.66	< 0.001
		HADS-D	− 6.79 (− 7.11 to 6.47)	− 0.36	− 4.50	0.72	0.64	0.36	0.70	< 0.001

Sen Sensitivity, Spe Specificity, YI Youden Index, AUC area under curve or C-statistic
^a Improvement was defined for QoL GHS (raw score, increased by 1 point), CD-RISC-10 (increased by 3 points), HADS-A (decreased by 1.5 points) and HADS-D (decreased by 1.5 points)
^b Deterioration was defined for QoL GHS (raw score, decreased by 1 point in global health status), CD-RISC-10 (decreased by 3 points), HADS-A (increased by 1.5 points) and HADS-D (increased by 1.5 points)

ISSN: 1477-7525